Bio-Rad Completes $70M Acquisition of AbD Serotec | GenomeWeb

NEW YORK (GenomeWeb News) - Bio-Rad Laboratories said today that it has closed its acquisition of antibody manufacturer AbD Serotec, a division of MorphoSys, for around €53 million ($70 million) in cash.

Bio-Rad announced its intention to acquire the business in December.

AbD Serotec offers more than 15,000 antibodies, kits, and accessories. It has an ISO 9001 and ISO 13485 certified production facility in the UK and additional facilities in Germany and the US.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: intellectual property landscape of CRISPR genome editing, and more.

A researcher has been convicted of conspiring to steal genetically engineered rice, Reuters reports.

Harvard Medical School's George Church says a woolly mammoth-elephant hybrid is only a few years away, according to the New Scientist.

Intel is ending its sponsorship of the International Science and Engineering Fair, the New York Times reports.